Edward Philpot
Omeros Corporation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Edward Philpot as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05972967 · Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabOmeros Corporation · completed · Paroxysmal Nocturnal Hemoglobinuria · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:28 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis.J Allergy Clin Immunol · 2007121 citationsRCR 4.6
- No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year.Allergy Asthma Proc · 2002103 citationsRCR 4.1
- Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis.Clin Exp Allergy · 200474 citationsRCR 3.0
- 72 citationsRCR 2.6
- Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast.Ann Allergy Asthma Immunol · 200365 citationsRCR 2.3
- Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents.Allergy Asthma Proc · 200763 citationsRCR 2.5
- Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn).Ann Allergy Asthma Immunol · 200344 citationsRCR 1.6
- Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients.Pediatrics · 200343 citationsRCR 1.6
- Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis.Ann Allergy Asthma Immunol · 200841 citationsRCR 1.7
- Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis.Otolaryngol Head Neck Surg · 200839 citationsRCR 1.5